OncoImmune cofounders Yang Liu and Pan Zheng tackled this problem ... OncoImmune has a robust pipeline, deep biology insights into CD24–Siglec and CTLA-4 signaling, and a very flexible approach ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback